Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S. Food and Drug Administration and to other global regulatory authorities April 13, 2026 -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, cont

Kailera Therapeutics has pulled off one of the largest biotech IPOs on record, raising $625 million as investor appetite for next-generation obesity drugs shows no signs of abating. The company priced 39.1 million shares at $16 each, which was the top end of its range. Certain existing shareholders had signaled confidence ahead of the debut, indicating plans to purchase about $225 million in the offering, or about 45% of the deal. The offering surpasses Moderna's debut in 2018 when the mRNA va

NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enst

Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing tr

Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of its RNA-modifying enzyme inhibitor. Proceeds from the financing will support the mid-stage study of a METTL3 inhibitor dubbed STC-15, which is designed to reprogram malignant progenitor cells by modulating mRNA methylation, according to an April 16 release. The trial, for which the first patient has now been dosed, will assess STC-15 as a monotherapy in various sarcoma indi

Rapid Medical™, a leading developer of active endovascular devices, today announced U.S. FDA clearance of the TIGERTRIEVER™ 25, the latest addition to its TIGERTRIEVER platform, along with the first clinical cases demonstrating its performance in treating large vessel occlusion (LVO) stroke. Designed specifically for large clot burden in proximal vessels, TIGERTRIEVER 25 combines a 53 mm capture length with proprietary real-time force control. This capability, unique to the TIGERTRIEVER platform

April 13, 2026 -- Veld Pharmaceuticals GmbH (“Veld”), a Switzerland-based pharmaceutical access and services company, today announced a collaboration with Chiesi Farmaceutici S.p.A (“Chiesi”) to expand patient access to nine rare-disease therapies through a Managed Access Program (MAP) across Africa. The program is designed to enable physicians, where permitted by local regulations, to prescribe these therapies to patients with serious unmet medical needs who meet defined medical eligibility

AbbVie presented Phase II results for mirvetuximab soravtansine (Elahere) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian cancer at the SGO 2026 Annual Meeting. The open-label IMGN853-0420 trial reported a confirmed objective response rate of 62.7% (95% CI, 52.6–72.1) in the primary FRα ≥50% subgroup after six cycles of combination induction therapy, the company said. The 125-patient trial enrolled adults with FRα-positive recurrent platinum-sensitive high-grade ep

April 13, 2026 -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI). The Phase 1 randomized, double-blind, placebo-controlled, sing

Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in patients with advanced ovarian cancer The ongoing Phase 3 RAINFOL-04 trial will further evaluate the combination in patients with recurrent platinum-sensitive ovarian cancer (PSOC) Genmab A/S (Nasdaq: GMAB) announced today new data demonstrating that rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, topoisomerase